Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Doc Payments For Coronary Stenting Will Drop Next Year, But Will Better Reflect Procedure Complexity

This article was originally published in The Gray Sheet

Executive Summary

New coding structure for coronary stenting recognizes more complex procedure with higher levels of Medicare reimbursement, but overall physician payments for percutaneous coronary interventions will go down in 2013.

You may also be interested in...



Oncology Society Proposes Changes To Radiation Therapy Procedure Codes

ASTRO proposes redesign of key radiation therapy codes as first part of its Payment Reform Action Plan.

Volcano: Learning To Thrive In A Declining PCI Market

Long used to a growing market driven by favorable demographics, cardiovascular companies are facing a declining PCI market, in the US and Europe at least, and are forced to shift their strategies to adapt. Volcano, for one, is articulating a new way to approach this declining market.

Drug-Coated Balloons Fuel Multibillion-Dollar Hopes

With a total market potential estimated in the multibillion-dollar range, the drug-coated balloon opportunity is attracting a growing list of competitors, including several leading multinational cardiovascular device companies that have entered the space via recent acquisitions. DCBs still need to prove their worth in large, long-term clinical trials, but the ultimate proving point for DCBs could center on cost: if they can offer an effective treatment option that is significantly less expensive than existing devices, DCBs may provide a compelling economic argument.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031740

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel